review quotes glp 1 Orforglipron: The First Approved Oral Non-Peptide GLP-1R Agonist for Obesity The right nutrition is key

Description

Protein digestion in human intestine as reflected in luminal, mucosal, and plasma amino acid concentrations after meals

39 In the SCALE trial, which enrolled 3,731 overweight or obese adults, liraglutide 3.0 mg daily was shown to reduce both systolic and diastolic BP, with average delta of 2.8 mmHg (95% CI [3.56, 2.09) and 0.9 mmHg (95% CI [1.41, 0.37), respectively

Tirzepatide produces 20-25%

Semaglutide medications work by activating the GLP-1 receptor alone, while tirzepatide medications activate both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, creating what is commonly described as a dual incretin mechanism

Tirzepatide: Safety Considerations for Different Profiles Semaglutide acts solely on GLP-1 receptors and shows excellent long-term safety data from cardiovascular outcome trials